CM
CATX icon

Caption Management’s Perspective Therapeutics CATX Stock Holding History

Caption Management’s Portfolio CATX Stock Details CATX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$205K Hold
60,000
– – ﹤0.01% 1463
2026
Q1 		$250K Buy
+60,000
New +$253K ﹤0.01% 1319

Other funds holding CATX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
SSC
Spruce Street Capital New York $510M AUM

Caption Management's CATX Position: Q2 2026 in Review

Caption Management held its Perspective Therapeutics (CATX) position steady in Q2 2026 at 60,000 shares worth $205K. The position accounts for ﹤0.01% of the portfolio, ranked #1463.

Caption Management first reported a position in CATX in Q1 2026 and has held it in 2 quarters since. The position peaked at $250K in Q1 2026. 131 funds tracked by Wall St. Rank hold CATX as of Q2 2026.

  • Caption Management held 60,000 shares of Perspective Therapeutics worth $205K as of Q2 2026.
  • Caption Management left its Perspective Therapeutics share count unchanged in Q2 2026.
  • Perspective Therapeutics made up ﹤0.01% of Caption Management's portfolio in Q2 2026, its #1463 holding.
  • Caption Management first reported a position in Perspective Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • Caption Management's Perspective Therapeutics position peaked at $250K in Q1 2026.
  • 131 funds tracked by Wall St. Rank held Perspective Therapeutics as of Q2 2026.

Based on Caption Management's 13F filing for Q2 2026, filed 14 Aug 2026.